Lutetium oxodotreotide ( 177 Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Table 5 Summary findings of sensitivity analyses for ¹⁷⁷Lu-Dotatate versus octreotide LAR 60 mg in GI-NET

Analysis	Costs, GBP			Quality-adjusted life expectancy, QALYs			ICER, GBP per QALY	% change from base case
Analysis	¹⁷⁷Lu-Dotatate	Octreotide 60 mg	Delta	¹⁷⁷Lu-Dotatate	Octreotide 60 mg	Delta	ICER, GBP per QALY	% change from base case
Base case analysis	84,990	49,289	35,701	3.25	1.92	1.33	26,830	―
Time horizon 5 years	75,715	44,896	30,818	2.37	1.71	0.66	47,013	75.23
Time horizon 10 years	86,710	48,758	37,951	2.95	1.89	1.06	35,986	34.13
Discount rate 1.5% clinical outcomes, 6% costs	80,896	46,711	34,185	3.48	2.00	1.48	23,104	−13.88
Efficacy; using MTC data for ¹⁷⁷Lu-Dotatate versus octreotide	89,728	49,022	40,706	3.09	1.90	1.19	34,478	28.51
Efficacy; using MTC data for ¹⁷⁷Lu-Dotatate versus everolimus (RADIANT-4)	89,728	68,045^a	21,683	3.09	2.53^a	0.56	39,169	45.99
PFS utility from NETTER-1	84,990	49,289	35,701	3.14	1.90	1.24	28,750	7.16
PFS utility from real world study^a	84,990	49,289	35,701	3.26	1.94	1.32	26,855	0.09
¹⁷⁷Lu-Dotatate RDI 86.4% (NETTER-1)	86,370	49,289	37,081	3.25	1.92	1.33	27,866	3.86
Including palliative care costs	91,354	63,464	27,890	3.16	1.73	1.43	19,544	−27.15

^aEverolimus
^bData from analysis of registry data from Guy’s and St Thomas’ Hospital, London. AAA data on file
HR hazard ratio, ICER incremental cost-effectiveness ratio, MTC mixed treatment comparison, PFS progression-free survival, QALY quality-adjusted life year, RDI relative dose intensity

ISSN: 1471-2407